In the BioHarmony Drug Report Database
Setmelanotide
Imcivree (setmelanotide) is a protein pharmaceutical. Setmelanotide was first approved as Imcivree on 2020-11-25. It has been approved in Europe to treat obesity. It is known to target melanocortin receptor 4, melanocortin receptor 3, melanocyte-stimulating hormone receptor, and melanocortin receptor 5. Imcivree’s patent is valid until 2027-10-13 (FDA).
Trade Name
|
Imcivree |
|---|---|
Common Name
|
setmelanotide |
ChEMBL ID
|
CHEMBL3301624 |
Indication
|
obesity |
Drug Class
|
Peptides: melanocortin receptor antagonists |
Image (chem structure or protein)